List of Onzetra Xsail drug patents

Onzetra Xsail is owned by Currax.

Onzetra Xsail contains Sumatriptan Succinate.

Onzetra Xsail has a total of 17 drug patents out of which 0 drug patents have expired.

Onzetra Xsail was authorised for market use on 27 January, 2016.

Onzetra Xsail is available in powder;nasal dosage forms.

Onzetra Xsail can be used as method of delivering sumatriptan to a nasal cavity, treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; method of delivering sumatriptan to a nasal cavity, method of drug delivery via the nasal cavity, acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity, acute treatment of migraine; treatment of migraine via delivery of sumatriptan via the nasal cavity; acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device.

The generics of Onzetra Xsail are possible to be released after 20 October, 2034.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8047202 CURRAX Nasal devices
Jul, 2023

(4 months from now)

US8327844 CURRAX Nasal delivery method
Oct, 2023

(7 months from now)

US9119932 CURRAX Nasal delivery device
Apr, 2024

(1 year, 2 months from now)

US7975690 CURRAX Nasal devices
Aug, 2025

(2 years from now)

US8590530 CURRAX Nasal delivery devices
Sep, 2025

(2 years from now)

US9108015 CURRAX Nasal delivery devices
Sep, 2025

(2 years from now)

US10124132 CURRAX Nasal delivery
Mar, 2027

(4 years from now)

US10398859 CURRAX Nasal delivery devices
Dec, 2027

(4 years from now)

US8875704 CURRAX Nasal administration
Apr, 2028

(5 years from now)

US10722667 CURRAX Nasal administration
Dec, 2028

(5 years from now)

US10076615 CURRAX Nasal delivery
Jul, 2029

(6 years from now)

US8550073 CURRAX Nasal delivery
Oct, 2029

(6 years from now)

US8899229 CURRAX Powder delivery devices
Aug, 2030

(7 years from now)

US9649456 CURRAX Nasal administration
Oct, 2030

(7 years from now)

US8978647 CURRAX Nasal delivery
Dec, 2030

(7 years from now)

US10478574 CURRAX Nasal administration
Nov, 2033

(10 years from now)

US10076614 CURRAX Nasal delivery devices
Oct, 2034

(11 years from now)

Drugs and Companies using SUMATRIPTAN SUCCINATE ingredient

Market Authorisation Date: 27 January, 2016

Treatment: Method of drug delivery via the nasal cavity; Acute treatment of migraine by delivering a powdered substance comprising sumatriptan via a breath-powered delivery device; Acute treatment of migraine; Treatment of migraine via delivery of sumatriptan via the nasal cavity; Method of delivering sumatriptan to a nasal cavity

Dosage: POWDER;NASAL

More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in